NEW RIVER PHARMA TO SOURCE ADHD DRUG API FROM AMRI

Albany Molecular Research, Inc. (AMRI), a global drug discovery company, has announced, that a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc., Financial terms were not disclosed. Under the agreement, AMRI will manufacture the active pharmaceutical ingredient, in New River's compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the US Food and Drug Administration. AMRI participated with New River in the development of the chemical process to manufacture NRP104.

Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34416§ionid=)